| epiR: tools for the analysis of epidemiological data M Stevenson, T Nunes, C Heuer, J Marshall, J Sanchez, R Thornton, ... R package version 2, 26, 2018 | 441 | 2018 |
| Correcting for measurement error in time-varying covariates in marginal structural models RP Kyle, EEM Moodie, MB Klein, M Abrahamowicz American journal of epidemiology 184 (3), 249-258, 2016 | 28 | 2016 |
| Routine HIV screening during intake medical evaluation at a county jail–Fulton County, Georgia, 2011–2012 AC Spaulding, CJ Bowden, BI Kim, MC Mann, L Miller, GR Mustaafaa, ... MMWR Morb Mortal Wkly Rep 62 (24), 495-7, 2013 | 23 | 2013 |
| Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance R Reves, CM Heilig, JM Tapy, L Bozeman, RP Kyle, CD Hamilton, N Bock, ... The International journal of tuberculosis and lung disease 18 (5), 571-580, 2014 | 21 | 2014 |
| Mixed impact of xpert® MTB/RIF on tuberculosis diagnosis in Cambodia SC Auld, BK Moore, RP Kyle, B Eng, K Nong, ES Pevzner, KK Eam, ... Public health action 6 (2), 129-135, 2016 | 11 | 2016 |
| Evaluating flexible modeling of continuous covariates in inverse-weighted estimators RP Kyle, EEM Moodie, MB Klein, M Abrahamowicz American journal of epidemiology 188 (6), 1181-1191, 2019 | 10 | 2019 |
| WCE: Weighted Cumulative Exposure Models MP Sylvestre, ME Beauchamp, RP Kyle, M Abrahamowicz Vienna, Austria: R Foundation for Statistical Computing, 2018 | 4 | 2018 |
| An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR … LJ Costa, TW LeBlanc, H Tesch, P Sonneveld, R Kyle, L Sinyavskaya, ... Journal of Clinical Oncology 41 (16_suppl), 6618-6618, 2023 | 1 | 2023 |
| Health-selective migration among patients with rheumatoid arthritis in Québec: a cohort study using administrative data JA Labrecque, RP Kyle, L Joseph, S Bernatsky Rheumatology international 36, 1275-1279, 2016 | 1 | 2016 |
| Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma LJ Costa, TW LeBlanc, H Tesch, P Sonneveld, RP Kyle, L Sinyavskaya, ... Future Oncology, 2024 | | 2024 |
| An Indirect Comparison of Elranatamab's Progression-Free Survival and Overall Survival from Magnetismm-3 Versus Real-World External Control Arms in Triple-Class Refractory … L Costa, TW LeBlanc, H Tesch, P Sonneveld, R Kyle, L Sinyavskaya, ... Blood 142, 6716, 2023 | | 2023 |
| P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY … L Costa, TW Leblanc, H Tesch, P Sonneveld, R Kyle, L Sinyavskaya, ... HemaSphere 7 (S3), e343009d, 2023 | | 2023 |
| Methodological Advances to Address Measurement Error and Model Misspecification in HIV Research R Kyle McGill University, 2023 | | 2023 |
| dash: An Interface to the Dash Ecosystem for Authoring Reactive Web Applications. R package version 0.9.3 C Parmer, RP Kyle, C Sievert, H Khan Vienna, Austria: R Foundation for Statistical Computing, 2021 | | 2021 |
| Evaluating The Efficacy And Safety Of Intermittent Tuberculosis (TB) Treatment When Isoniazid (INH) Cannot Be Used R Reves, CD Hamilton, J Tapy, M Narita, RP Kyle, C Heilig, L Bozeman, ... C16. NEW TUBERCULOSIS TREATMENT OPTIONS FOR ACTIVE AND LATENT DISEASE, A4040 …, 2011 | | 2011 |
Erica EM MoodieMcGill UniversityVerified email at mcgill.ca
